37 citations · 75 across the 30 of their papers we have counts for
6 papers · 1 filter
A Novel Statistical Test for Treatment Differences in Clinical Trials using a Response Adaptive Forward Looking Gittins Index Rule
Helen Yvette Barnett, Sofia S Villar, Helena Geys +1
The most common objective for response adaptive clinical trials is to seek to ensure that patients within a trial have a high chance of receiving the best treatment available by al…
Bayesian sample size determination using commensurate priors to leverage pre-experimental data
Haiyan Zheng, Thomas Jaki, James M. S. Wason
This paper develops Bayesian sample size formulae for experiments comparing two groups. We assume the experimental data will be analysed in the Bayesian framework, where pre-experi…
A Seamless Phase I/II Platform Design with a Time-To-Event Efficacy Endpoint for Potential COVID-19 Therapies
Thomas Jaki, Helen Barnett, Andrew Titman +1
In the search for effective treatments for COVID-19, initial emphasis has been on re-purposed treatments. To maximise the chances of finding successful treatments, novel treatments…
Adding experimental treatment arms to Multi-Arm Multi-Stage platform trials in progress
Thomas Burnett, Franz König, Thomas Jaki
Multi-Arm Multi-Stage (MAMS) platform trials are an efficient tool for the comparison of several treatments. Suppose we wish to add a treatment to a trial already in progress, to a…
Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs
Thomas Burnett, Pavel Mozgunov, Philip Pallmann +3
Adaptive designs for clinical trials permit alterations to a study in response to accumulating data in order to make trials more flexible, ethical and efficient. These benefits are…
Endpoints for randomized controlled clinical trials for COVID-19 treatments
Lori E Dodd, Dean Follmann, Jing Wang +12
Introduction: Endpoint choice for randomized controlled trials of treatments for COVID-19 is complex. A new disease brings many uncertainties, but trials must start rapidly. COVID-…